Immune protection against tuberculosis--when is immunotherapy preferable to vaccination? (Q37828296)

24 August 2017

1 reference

title

Immune protection against tuberculosis--when is immunotherapy preferable to vaccination? (English)

1 reference

24 August 2017

0 references

1 reference

J M Grange

1

1 reference

24 August 2017

L Rosa Brunet

series ordinal

2

1 reference

24 August 2017

H L Rieder

series ordinal

3

1 reference

24 August 2017

publication date

12 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

91

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

179-185

1 reference

Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

BCG--different strains, different vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

[Clarification of the Luebeck infant tuberculosis]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

The success and failure of BCG - implications for a novel tuberculosis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

New vaccines for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Incidence and nature of human tuberculosis due to bovine tubercle bacilli in South-East England: 1977-1987

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Commentary: Reconciling historical epidemiological, bacteriological and immunological observations in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Exogenous reinfection in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

The three Es of cancer immunoediting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Immunology of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

7 January 2021

Immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

What's good for the host is good for the bug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

New insights into the function of granulomas in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Much's granules revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

The mystery of the mycobacterial 'persistor'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

On the nature of Mycobacterium tuberculosis-latent bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Immune responses to tuberculosis in developing countries: implications for new vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Th2 cytokines in susceptibility to tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Understanding latent tuberculosis: a moving target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

The common mycobacterial antigens and their importance in the treatment of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

M. tuberculosis: immunology and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

The use of mycobacterial adjuvant-based agents for immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Influence of Mycobacterium bovis Bacillus Calmette-Guerin on Antibody and Cytokine Responses to Human Neonatal Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Lower Hookworm Incidence, Prevalence, and Intensity of Infection in Children with a Bacillus Calmette‐Guérin Vaccination Scar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

BCG vaccination and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Prior BCG vaccination improves survival of Gambian patients treated for pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

BCG vaccination status may predict sputum conversion in patients with pulmonary tuberculosis: a new consideration for an old vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

7 January 2021

Environmental echoes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Mechanisms of disease: the hygiene hypothesis revisited.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

How environmental mycobacteria may predetermine the protective efficacy of BCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Mycobacterium vaccae immunotherapy for treating tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

Studies of mycobacterial antigens, with special reference to Mycobacterium leprae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.12.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2010.12.004

1 reference

24 August 2017

1 reference